# UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

> **NCT07500805** · PHASE1 · NOT_YET_RECRUITING · sponsor: **UTC Therapeutics Inc.** · enrollment: 21 (estimated)

## Conditions studied

- CD70-positive Advanced Renal Clear Cell Carcinoma

## Interventions

- **BIOLOGICAL:** UCL70805F

## Key facts

- **NCT ID:** NCT07500805
- **Lead sponsor:** UTC Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07500805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07500805, "UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07500805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*